Recent Press Releases

Gilead Sciences Announces Third Quarter 2014 Financial Results

Gilead Sciences Announces Third Quarter 2014 Financial Results Product Sales of $5.97 billion - - Sovaldi Sales of $2.80 billion - - Non-GAAP EPS of $1.84 per share - - Revised 2014 Full Year...

Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans

Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018

NEW YORK,

Allergan Reports Third Quarter 2014 Operating Results

(IRVINE, Calif., October 27, 2014) - Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended September 30, 2014. Allergan also announced that its Board of Directors has...

Universal Health Services, Inc. Reports Financial Results For The Three And Nine Months Ended September 30, 2014

Consolidated Results of Operations, As Reported - Three and nine-month periods ended September 30, 2014 and 2013:

KING OF PRUSSIA, Pa.

Assistance Programs, Dividends, Campaigns, Drug Recommendations, and Research Collaborations - Research Reports on Duke Energy, Exelon, Marriott, Vertex and AstraZeneca

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 27, 2014

DURECT Provides Update on REMOXY® and POSIDUR™ Programs

CUPERTINO, Calif., Oct.

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD...

CSL to acquire Novartis' influenza vaccine business

Melbourne, Australia — 27/10/2014 CSL Limited has today announced an agreement to acquire Novartis' global influenza vaccine business for US$275 million, which will be combined with...

Valeant Delivers Letter To Allergan Board

10/27/2014 · Prepared to Improve Offer And Provide Value of at Least $200 a Share · Urges Allergan Board to Take Control of Process LAVAL, Quebec, Oct. 27, 2014 /PRNewswire/...

CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis, strengthening mortality benefit and reinforcing safety profile

CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis, strengthening mortality benefit and reinforcing safety profile Pooled analysis of ASCEND and two CAPACITY phase III trials...

Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million

Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million...

Novo Nordisk receives subpoena from US Attorney

Novo Nordisk receives subpoena from US Attorney Bagsværd, Denmark 24 October 2014 - Novo Nordisk today announced that it has been served with a subpoena by the office of the US Attorney for the...

Pfizer Wins SUTENT® Patent Case In Delaware District Court

Pfizer Wins SUTENT® Patent Case In Delaware District Court Oct. 23, 2014 - Pfizer Inc. announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the...

Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results

Posts Third Quarter GAAP EPS of $0.43 and Non-GAAP EPS of $0.45 Achieves Significant Regulatory Milestones for PD-1 Inhibitor Opdivo Launches Daklinza-Based Regimens for HCV Patients in Japan and...

Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend

Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend The board of directors of Pfizer Inc. today declared a 26-cent fourth-quarter 2014 dividend on the company's common stock, payable December 2,...